CD8A and primary cutaneous T-cell non-Hodgkin lymphoma: Moreover, with exhibiting CD8 and CD11b co-expression and symptoms like splenomegaly and lymphadenopathy, it is a valuable tool for exploring late-stage CTCL’s advancement and treatment (Harro et al., 2021).